~ Beyond Vitamins - A Closer Look at Life Extension Mix, Part 4 - References


1. Li R, et al. Trends in fruit and vegetable consumption among adults in 16 US states: Behavioral Risk Factor Surveillance System, 1990-1996. Am J Public Health 2000 May;90(5):777-81.

2. Walaszek Z, et al. D-glucaric acid content of various fruits and vegetables and cholesterol-lowering effects of dietary D-glucarate in the rat. Nutrition Research (United States) 1996, 16/4 (673-681).

3. Dwivedi C, et al. Effect of calcium glucarate on beta-glucoronidase activity and glucarate content of certain vegetable and fruits. Biochemical Medicine and Metabolic Biology (United States) 1990, 43/2 (83-92).

4. Oredipe OA, et al. Dietary glucarate-mediated inhibition of initiation of diethylnitrosamine-induced hepatocarcinogenesis. Toxicology; 74 (2-3). 1992. 209-222.

5. Cohen LA, et al. Wheat bran and psyllium diets: effects on N-methylnitrosourea-induced mammary tumorigenesis in F344 rats. J Natl Cancer Inst 1996 Jul 3;88(13):899-907.

6. Walaszek Z, et al. Dietary glucarate-mediated reduction of sensitivity of murine strains to chemical carcinogenesis. Cancer Lett 1986 Oct;33(1):25-32.

7. Walaszek Z, et al. Antiproliferative effect of dietary glucarate on the Sprague-Dawley rat mammary gland. Cancer Lett 1990 Jan;49(1):51-7.

8. Heerdt A.S, et al. Calcium glucarate as a chemopreventive agent in breast cancer. Israel Journal of Medical Sciences (Israel) 1995, 31/2-3 (101-105).

9. Bhatnagar R, et al. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochemical Pharmacology (United Kingdom) 1991, 41/10 (1471-1477).

10. Curley Jr. R.W, et al. Activity of D-glucarate analogues: Synergistic antiproliferative effects with retinoid in cultured human mammary tumor cells appear to specifically require the D-glucarate structure. Life Sciences 1994, 54/18 (1299-1303).

11. Slaga,T. J. 1999. D-Glucarate a Nutrient Against Cancer. Keats Publishing - Lincolnwood, Chicago Illiinois. page 33.

12. Abou-Issa H, et al. Antitumour synergism between non-toxic dietary combinations of isotretinoin and glucarate. European Journal of Cancer Part A: General Topics (United Kingdom) 1992, 28/4-5 (784-788).

13. Walaszek Z, et al. Dietary glucarate as anti-promoter of 7,12- dimethylbenz[a]anthracene-induced mammary tumorigenesis. Carcinogenesis 1986 Sep;7(9):1463-6.

14. Abou-Issa H, et al. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res 1995 May-Jun; 15(3):805-10.

15. Oredipe O.A, et al. Chemopreventative activity of dietary glucarate on azoxymethane-induced altered hepatic foci in rats. Research Communications in Chemical Pathology and Pharmacology 1989, 65/3 (345-359).

16. Walaszek Z. Potential use of D-glucaric acid derivatives in cancer prevention. Cancer Lett 1990 Oct 8;54(1-2):1-8.

17. Dwivedi C, et al. Effects of the experimental chemopreventative agent, glucarate, on intestinal carcinogenesis in rats. Carcinogenesis 1989 Aug; 10(8):1539-41.

18. Dutton, G.J. 1980. Glucuronidation of Drugs and other Compounds. Boca Raton, FL.: CRC Press.

19. Walaszek Z. Potential use of D-glucaric acid derivatives in cancer prevention. Cancer Letters (Ireland) 1990, 54/1-2 (1-8).

20. Boone C.W, et al. Screening for chemopreventive (anticarcinogenic) compounds in rodents. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis (Netherlands) 1992, 267/2 (251-255).

21. Walaszek Z. Chemopreventive properties of D-glucaric acid derivatives. Cancer Bulletin (United States) 1993, 45/5 (453-457).

22. Loarca-Pina G, et al. Inhibitory effects of ellagic acid on the direct-acting mutagenicity of aflatoxin B1 in the Salmonella microsuspension assay. Mutat Res 1998 Feb 26;398(1-2):183-7.

23. Barch D.H, et al. Structure-function relationships of the dietary anticarcinogen ellagic acid. Carcinogenesis (United Kingdom) 1996, 17/2 (265-269).

24. Narayanan B.A, et al. p53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Letters (Ireland) 1999, 136/2 (215-221).

25. Soni K.B, et al. Protective effect of food additives on aflatoxin-induced mutagenicity and hepatocarcinogenicity. Cancer Letters (Ireland) 1997, 115/2 (129-133).

26. Takagi A, et al. Inhibitory effects of vitamin E and ellagic acid on 8-hydroxydeoxyguanosine formation in liver nuclear DNA of rats treated with 2-nitropropane. Cancer Letters (Ireland) 1995, 91/1 (139-144).

27. Castonguay A, et al. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by hamster respiratory tissues cultured with ellagic acid. Cancer Letters (Ireland) 1989, 46/2 (93-105).

28. Hakkinen, S, et al. Screening of selected flavonoids and phenolic acids in 19 berries. Food Research International 1999, 32 (5) 345-353.

29. Maas, J. L, et al. Ellagic acid, an anticarcinogen in fruits, especially in strawberries: a review. HortScience vol. 26 (1): p.10-14, 1991.

30. Constantinou A, et al. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutrition and Cancer (United States) 1995, 23/2 (121-130).

31. Stoner GD, et al. Lung tumors in strain A mice: application for studies in cancer chemoprevention. J Cell Biochem Suppl 1993;17F:95-103.

32. Barch DH, et al. Ellagic acid induces NAD(P)H:quinone reductase through activation of the antioxidant responsive element of the rat NAD(P)H:quinone reductase gene. Carcinogenesis 1994 Sep;15(9):2065-8.

33. Teel R.W, et al. Ellagic acid metabolism and binding to DNA in organ explant cultures of the rat. Cancer Letters (Ireland) 1987, 36/2 (203-211).

34. Teel R.W. Ellagic acid binding to DNA as a possible mechanism for its antimutagnic and anticarcinogenic action. Cancer Letters (Ireland) 1986, 30/3 (329-336).

35. Thresiamma K.C, et al. Inhibition of liver fibrosis by ellagic acid. Indian Journal of Physiology and Pharmacology (India) 1996, 40/4 (363-366).

36. Dixit R, et al. Inhibition of N-methyl-N-nitrosourea-induced mutagenicity and DNA methylation by ellagic acid. Proceedings of the National Academy of Sciences of the United States of America (United States) 1986, 83/21 (8039-8043).

37. Stoner GD, et al. Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 1995;22:169-80.

38. Teel R.W, et al. Antimutagenic effects of polyphenolic compounds. Cancer Letters (Ireland) 1992, 66/2 (107-113).

39. Wilson T, et al. The effect of ellagic acid on xenobiotic metabolism by cytochrome P-450IIE1 and nitrosodimethylamine mutagenicity. Cancer Letters (Ireland) 1992, 61/2 (129-134).

40. Thresiamma K.C, et al. Protective effect of curcumin, ellagic acid and bixin on radiation induced genotoxicity. Journal of Experimental and Clinical Cancer Research (Italy) 1998, 17/4 (431-434).

41. Castonguay A. Pulmonary carcinogenesis and its prevention by dietary polyphenolic compounds. Ann N Y Acad Sci 1993 May 28;686:177-85.

42. Stoner G.D, et al. Isothiocyanates and plant polyphenols as inhibitors of lung and esophageal cancer. Cancer Letters (Ireland) 1997, 114/1-2 (113-119).

43. Loarca-Pina G, et al. Antimutagenicity of ellagic acid against aflatoxin Binf 1 in the Salmonella microsuspension assay. Mutation Research - Environmental Mutagenesis and Related Subjects (Netherlands) 1996, 360/1 (15-21).

44. Barch D.H, et al. Dietary ellagic acid reduces the esophageal microsomal metabolism of methylbenzylnitrosamine. Cancer Letters (Ireland) 1989, 44/1 (39-44).

45. Castonguay A, et al. Antitumorigenic and antipromoting activities of ellagic acid, ellagitannins and oligomeric anthocyanin and procyanidin. International Journal of Oncology (Greece) 1997, 10/2 (367-373).

46. Rao C.V, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Research 1991, 51/17 (4528-4534).

47. Cozzi R, et al. Taurine and ellagic acid: Two differently-acting natural antioxidants. Environmental and Molecular Mutagenesis 1995, 26/3 (248-254).

48. Ahn D, et al. The effects of dietary ellagic acid on rat hepatic and esophageal mucosal cytochromes P450 and phase II enzymes. Carcinogenesis (United Kingdom) 1996, 17/4 (821-828).

49. Daniel E.M, et al. The effects of ellagic acid and 13-cis-retinoic acid on N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats. Cancer Letters (Ireland) 1991, 56/2 (117-124).

50. Francis A.R, et al. Modification of the mutagenicity of aflatoxin Binf 1 and N-methyl-N'-nitro-N-nitrosoguanidine by certain phenolic compounds. Cancer Letters (Ireland) 1989, 45/3 (177-182).

51. Suzuki M, et al. Protective effects of antioxidants on experimental liver injuries. Yakugaku Zasshi (Japan) 1990, 110/9 (697-701).

52. Thresiamma K.C, et al. Protective effect of curcumin, ellagic acid and bixin on radiation induced lipid peroxidation. Journal of Experimental and Clinical Cancer Research (Italy) 1995, 14/4 (427-430).

53. Frank A.A, et al. Ellagic acid protects rat embryos in culture from the embryotoxic effects of N-methyl-N-nitrosourea. Teratology 1992, 46/2 (109-115).

54. Bradlow HL, et al. Phytochemicals as modulators of cancer risk. Adv Exp Med Biol 1999;472:207-21.

55. Kelloff GJ, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000 Feb;130(2S Suppl):467S-471S.

56. Wang X, et al. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer 1999 Jun;80(8):1223-30.

57. Lee SK, et al. Modulation of in vitro biomarkers of the carcinogenic process by chemopreventive agents. Anticancer Res 1999 Jan-Feb;19(1A):35-44.

58. Hecht SS, et al. Chemoprevention of cancer by isothiocyanates, modifiers of carcinogen metabolism. J Nutr 1999 Mar;129(3):768S-774S.

59. Zhang Y, et al. Mechanism of differential potencies of isothiocyanates as inducers of anticarcinogenic Phase 2 enzymes. Cancer Res 1998 Oct 15;58(20):4632-9.

60. Kelloff GJ, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 1996;26:1-28.

61. Gamet-Payrastre L, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000 Mar 1;60(5):1426-33.

62. Kong AN, et al. Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharm Res 2000 Feb;23(1):1-16.

63. Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis 2000 Jun;21(6):1175-1182.

64. Singletary K, et al. Inhibition of benzo[a]pyrene- and 1,6-dinitropyrene-DNA adduct formation in human mammary epithelial cells bydibenzoylmethane and sulforaphane. Cancer Lett 2000 Jul 3; 155(1):47-54.

65. Kopelovich L, et al. Progress in cancer chemoprevention. Ann N Y Acad Sci 1999;889:1-13.

66. Yu R, et al. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 2000 Jan 28;275(4):2322-7.

67. Langouet S, et al. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem Res Toxicol 2000 Apr;13(4):245-52.

68. van Lieshout EM, et al. Effects of the sulforaphane analog compound 30, indole-3-carbinol, D-limonene or relafen on glutathione S-transferases and glutathione peroxidase of the rat digestive tract. Biochim Biophys Acta 1998 Mar 2;1379(3):325-36.

69. Hirano T, et al. Antiproliferative effects of synthetic and naturally occurring flavonoids on tumor cells of the human breast carcinoma cell line, ZR-75-1. Res Commun Chem Pathol Pharmacol 1989 Apr;64(1):69-78.

70. Kuiper GG, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998 Oct;139(10):4252-63.

71. Noroozi M, et al. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 1998 Jun;67(6):1210-8.

72. Wang IK, et al. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999 Oct;35(10):1517-25.

73. Takahashi T, et al. Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Biosci Biotechnol Biochem 1998 Nov;62(11):2199-204.

74. Boege F, et al. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase. J Biol Chem 1996 Jan 26;271(4):2262-70.

75. Kawaii S, et al. Effect of citrus flavonoids on HL-60 cell differentiation. Anticancer Res 1999 Mar-Apr; 19(2A):1261-9.

76. Yin F, et al. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 1999 Sep-Oct;19(5B):4297-303.

77. Yin F, et al. Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 1999 Apr;9(4):369-76.

78. Richter M, et al. Quercetin-induced apoptosis in colorectal tumor cells: possible role of EGF receptor signaling. Nutr Cancer 1999;34(1):88-99.

79. Reddy KB, et al. Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int J Cancer 1999 Jul 19;82(2):268-73.

80. Podyma KA, et al. Difference of hyaluronidase produced by human tumor cell lines with hyaluronidase present in human serum as revealed by zymography. Biochem Biophys Res Commun 1997 Dec 18;241(2):446-52.

81. Fotsis T, et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998 Dec;12(4):649-66.

82. Birt DF, et al. Diet intervention for modifying cancer risk. Prog Clin Biol Res 1996;395:223-34.

83. Lee SC, et al. Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells. Anticancer Res 1998 Mar-Apr;18(2A):1117-21.

84. Song DH, et al. Endogenous protein kinase CK2 participates in wnt signaling in mammary epithelial cells. J Biol Chem 2000 Aug 4;275(31):23790-7.

85. Makela S, et al. Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998 Mar;217(3):310-6.

86. Eaton EA, et al. Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos 1996 Feb;24(2):232-7.

87. Giles D, et al. Effect of structurally related flavones/isoflavones on hydrogen peroxide production and oxidative DNA damage in phorbol ester-stimulated HL-60 cells. Nutr Cancer 1997;29(1):77-82.

88. Nielsen SE, et al. Effect of parsley (Petroselinum crispum) intake on urinary apigenin excretion, blood antioxidant enzymes and biomarkers for oxidative stress in human subjects. Br J Nutr 1999 Jun;81(6):447-55.

89. McVean M, et al. Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis 2000 Apr;21(4):633-9.

90. Dobrydneva Y, et al. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br J Pharmacol 1999 Sep;128(1):149-57.

91. Trochon V, et al. Apigenin inhibits endothelial-cell proliferation in G(2)/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression. Int J Cancer 2000 Mar 1;85(5):691-6.

92. Liang YC, et al. Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophages. Carcinogenesis 1999 Oct;20(10):1945-52.

93. Yanoshita R, et al. Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res 1996 Nov;45(11):546-9.

94. Huang YT, et al. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol 1999 Nov;128(5):999-1010.

95. Ma JY, et al. A sesquiterpene lactone glucoside from Ixeris denticulata f. pinnatipartita. Phytochemistry 1999 Jan;50(1):113-5.

96. Matsukawa Y, et al. Genistein arrests cell cycle progression at G2-M. Cancer Res 1993 Mar 15;53(6):1328-31.

97. Post JF, et al. Growth inhibitory effects of bioflavonoids and related compounds on human leukemic CEM-C1 and CEM-C7 cells. Cancer Lett 1992 Dec 24;67(2-3):207-13.

98. Sadzuka Y, et al. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 1997 Jun 16;92(1):1-7.

99. Noroozi M, et al. Effects of flavonoids and vitamin C on oxidative DNA damage to human lymphocytes. Am J Clin Nutr 1998 Jun;67(6):1210-8.

100. Holland MB, et al. Estrone-induced cell proliferation and differentiation in the mammary gland of the female Noble rat. Carcinogenesis 1995 Aug;16(8):1955-61.

101. Wang C, et al. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 1994 Aug;50(3-4):205-12.

102. Joshi S.C, et al. Inhibition of 17beta-estradiol formation by isoflavonoids and flavonoids in cultured JEG-3 cells: Search for aromatase-targeting dietary compounds. Journal of Medicinal Food 1999, 2/3-4 (235-238).

103. Holland MB, et al. Estrone-induced cell proliferation and differentiation in the mammary gland of the female Noble rat. Carcinogenesis 1995 Aug;16(8):1955-61.

104. Elangovan V, et al. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis. Cancer Lett 1994 Nov 25;87(1):107-13.

105. Elangovan V, et al. Chemopreventive potential of dietary bioflavonoids against 20-methylcholanthrene-induced tumorigenesis. Cancer Lett 1994 Nov 25;87(1):107-13.

106. Makino T, et al. Inhibitory effect of Perilla frutescens and its phenolic constituents on cultured murine mesangial cell proliferation. Planta Med 1998 Aug;64(6):541-5.

107. Shimoi K, et al. Radioprotective effects of antioxidative plant flavonoids in mice. Mutat Res 1996 Feb 19;350(1):153-61.

108. Garcia-Closas R, et al. Intake of specific carotenoids and flavonoids and the risk of gastric cancer in Spain. Cancer Causes Control 1999 Feb;10(1):71-5.

109. McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Med Hypotheses 1999 May;52(5):401-6.

110. Furukawa Y. [Enhancement of glucose-induced insulin secretion and modification of glucose metabolism by biotin]. Nippon rinsho (JAPAN) Oct 1999, 57 (10) p2261-9.

111. Koutsikos D, et al. Oral glucose tolerance test after high-dose i.v. biotin administration in normoglucemic hemodialysis patients. Ren Fail 1996 Jan;18(1):131-7.

112. McCarty MF. Toward a wholly nutritional therapy for type 2 diabetes. Med Hypotheses 2000 Mar;54(3):483-7.

113. McCarty MF. Toward practical prevention of type 2 diabetes. Cancer Treat Rev 2000 May;54(5):786-793.

114. Romero-Navarro G, et al. Biotin regulation of pancreatic glucokinase and insulin in primary cultured rat islets and in biotin-deficient rats. Endocrinology Oct 1999, 140 (10) p4595-600.

115. McCarty MF. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type II diabetes. Medical hypotheses (ENGLAND) May 1999, 52 (5) p401-6.

116. Zhang H, et al.Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. Journal of Nutritional Science and Vitaminology (JAPAN) Jun 1997, 43 (3) p271-80.

117. Borboni P, et al. Effect of biotin on glucokinase activity, mRNA expression and insulin release in cultured beta-cells. Acta diabetologica (GERMANY) Jul 1996, 33 (2) p154-8.

118. Chauhan J, et al. Transcriptional regulation of the glucokinase gene by biotin in starved rats. Journal of Biological Chemistry Jun 5 1991, 266 (16) p10035-8.

119. Spence JT, et al. Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. Journal of Biological Chemistry May 25 1984, 259 (10) p6393-6.

120. McCarty M.F. Towards practical prevention of type 2 diabetes. Medical Hypotheses (United Kingdom) 2000, 54/5 (786-793).

121. Hsieh Y.T.L, et al. Effect of biotin on the regulation of glucokinase in the intact rat. Nutrition Research 1992, 12/6 (787-799).

122. Baas P, et al. Effect of N-acetylcysteine on Photofrin-induced skin photosensitivity in patients. Lasers Surg Med 1995;16(4):359-67.

123. Mietus-Snyder M, et al. Regulation of scavenger receptor expression in smooth muscle cells by protein kinase C: a role for oxidative stress. Arterioscler Thromb Vasc Biol 1997 May;17(5):969-78.

124. De Flora S, et al. Attenuation of influenza -like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J (Denmark) Jul 1997, 10 (7) p1535-41.

125. Ballke EH, et al. The transmural potential difference (tmpd) of the bronchial mucosa in children with chronic nonspecific respiratory diseases (CF- and non-CF-children). Zeitschrift fur Erkrankungen der Atmungsorgane (GERMANY, EAST) 1988, 171 (2) p132-4.

126. Rogers D.F., et al. Oral N-acetylcysteine speeds reversal of cigarette smoke-induced mucous cell hyperplasia in the rat. Experimental Lung Research 1988, 14/1 (19-35).

127. Jeffery P.K. Anti-inflammatory drugs and experimental bronchitis. European Journal of Respiratory Diseases (Denmark) 1986, 69/SUPPL. 146 (245-257).

128. Jeffery P.K., et al. Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. European Journal of Respiratory Diseases (Denmark) 1985, 66/SUPPL. 139 (117-122).

129. Newman T.J., et al. Acetaminophen hepatotoxicity and malnutrition. American Journal of Gastro-enterology (United States) 1979, 72/6 (647-650).

130. Prescott L.F., et al. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. European Journal of Clinical Pharmacology (Germany) 1989, 37/5 (501-506).

131. Beckett GJ, et al. Intravenous N-acetylcysteine, hepatotoxicity and plasma glutathione S-transferase in patients with paracetamol overdosage. Human & Experimental Toxicology (ENGLAND) May 1990, 9 (3) p183-6.

132. Chahine R, et al. Protective effects of taurine against reperfusion-induced arrhythmias in isolated ischemic rat heart. Arzneimittelforschung 1998 Apr;48(4):360-4.

133. Sharma JN, et al. Suppressive effects of eugenol and ginger oil on arthritic rats. Pharmacology 1994 Nov;49(5):314-8.

134. Verma SK, et al. Effect of ginger on platelet aggregation in man. Indian J Med Res 1993 Oct;98:240-2.

135. Bordia A, et al. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1997 May;56(5):379-84.

136. Sharma SS, et al. Antiemetic efficacy of ginger (Zingiber officinale) against cisplatin-induced emesis in dogs. J Ethnopharmacol 1997 Jul;57(2):93-6.

137. Park KK, et al. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett 1998 Jul 17;129(2):139-44.

138. Katiyar SK, et al. Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. Cancer Res 1996 Mar 1;56(5):1023-30.

139. Keevil JG, et al. Grape juice, but not orange juice or grapefruit juice, inhibits human platelet aggregation. J Nutr 2000 Jan;130(1):53-6.

140. Ye X, et al. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol Cell Biochem 1999 Jun;196(1-2):99-108.

141. Bomser JA, et al. Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds. Cancer Lett 1999 Jan 29;135(2):151-7.

142. Girodon F, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial. MIN. VIT.AOX. geriatric network. Arch Intern Med 1999 Apr 12;159(7):748-54.

143. Kuttan R. Collagen treated with (+)-catechin becomes resistant to the action of mammalian collagenase. Experientia (SWITZERLAND) Mar 15 1981, 37(3) p221-3.

144. Tixier J.M., et al. Evidence by in vivo and in vitro studies that binding of pycnogenols to elastin affects its rate of degradation by elastases. Biochemical Pharmacology (United Kingdom) 1984, 33/24 (3933-3939).

145. Isomatsu Y., et al. [Clinical study on prophylaxis of diacetyl-glucaro-(1-4) (6-3) dilactone for recurrence of bladder cancer]. Gan to kagaku ryoho (JAPAN) Sep 1983, 10 (9) p1958-62.

146. Wada S., et al. [Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. Hinyokika kiyo (JAPAN) Jan 1992, 38 (1) p19-24.

147. Walaszek Z., et al. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev 1997;21(2):178-90.

148. Urban T., et al. Neutrophil function and glutathione-peroxidase (GSH-px) activity in healthy individuals after treatment with N-acetyl-L-cysteine. Biomed Pharmacother 1997;51(9):388-90.

149. Baik HW., et al. Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999;19:357-77.

150. Loew D., et al. Studies on vitamin B12 status in the elderly--prophylactic and therapeutic consequences. Int J Vitam Nutr Res 1999 May;69(3):228-33.

151. Bachli E., et al. [Diagnosis of vitamin B12 deficiency: only apparently child's play]. Schweiz Med Wochenschr 1999 Jun 12;129(23):861-72.

152. Ravina A., et al. Reversal of corticosteroid-induced diabetes mellitis with supplemental chromium. Diabetic Medicine (United Kingdom) 1999, 16/2 (164-167).

153. Reiter R., et al. Selenium and drug metabolism--I. Multiple modulations of mouse liver enzymes. Biochem Pharmacol 1983 Oct 15;32(20):3063-7.

154. Pfohl-Leszkowicz A., et al. Effect of cobalamin derivatives on in vitro enzymatic DNA methylation: methylcobalamin can act as a methyl donor. Biochemistry 1991 Aug 13;30(32):8045-51.

155. Newman PE. Can reduced folic acid and vitamin B12 levels cause deficient DNA methylation producing mutations which initiate atherosclerosis? Med Hypotheses 1999 Nov;53(5):421-4.

156. Slattery M.L., et al. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999 Jun;8(6):513-8.

157. Johnson EJ, et al. Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr 2000 Jun;71(6):1555-62.

158. Siems WG., et al. Lycopene and beta-carotene decompose more rapidly than lutein and zeaxanthin upon exposure to various pro-oxidants in vitro. Biofactors 1999;10(2-3):105-13.

159. Soholm B. Clinical improvement of memory and other cognitive functions by Ginkgo biloba: review of relevant literature. Adv Ther 1998 Jan-Feb;15(1):54-65.

160. Carr AC, Tijerina T, Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 2000 Mar 1;346 Pt 2:491-9.

Free Shipping in the Continental U.S. on Orders over $50
The statements made here have not been evaluated by the FDA. The foregoing statements are based upon sound and reliable studies, and are meant for informational purposes. Consult with your medical practitioner to determine the underlying cause of your symptoms. Please always check your purchase for possible allergins and correct dosage on the bottle before use.

While we work to ensure that product information is correct, on occasion manufacturers may alter their ingredient lists. Actual product packaging and materials may contain more and/or different information than that shown on our Web site. We recommend that you do not solely rely on the information presented and that you always read labels, warnings, and directions before using or consuming a product. For additional information about a product, please contact the manufacturer. Content on this site is for reference purposes and is not intended to substitute for advice given by a physician, pharmacist, or other licensed health-care professional. You should not use this information as self-diagnosis or for treating a health problem or disease. Contact your health-care provider immediately if you suspect that you have a medical problem. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or health condition. Life Ex Online assumes no liability for inaccuracies or misstatements about products.